Hostname: page-component-54dcc4c588-dbm8p Total loading time: 0 Render date: 2025-10-05T00:36:18.124Z Has data issue: false hasContentIssue false
  • English
  • Français

Lithium and carbamazepine in bipolar disorder

Published online by Cambridge University Press:  18 September 2015

P. Moleman ,
E.G.Th.M. Hartong ,
C.A.L. Hoogduin ,
T.G. Broekman ,
W.A. Nolen  and
The LitCar Group
P. Moleman*
Affiliation:
Institute for Clinical Psychiatric Research's Gravenhage Moleman Research, Consultants on Human Psychopharmacology, Amerongen, The Netherlands
E.G.Th.M. Hartong
Affiliation:
Institute for Clinical Psychiatric Research's Gravenhage
C.A.L. Hoogduin
Affiliation:
Institute for Clinical Psychiatric Research's Gravenhage Dept. of Clinical Psychology, K.U. Nijmegen
T.G. Broekman
Affiliation:
Bureau Beta, Nijmegen, The Netherlands
W.A. Nolen
Affiliation:
Institute for Clinical Psychiatric Research's Gravenhage Department of Psychiatry, University Medical Center Utrecht and Altrecht, Utrecht, The Netherlands
*
Moleman Research BV, Burg. Jhr. H. van den Boschstraat 11, 3958 CA Amerongen, The Netherlands
Get access Rights & Permissions [Opens in a new window]

Abstract

Lithium is considered first choice in the prevention of prospective episodes in patients with bipolar disorder. However, efficacy is not satisfactory in all patients and side effects sometimes prevent the use of lithium. It is argued that efficacy in clinical practice may be less impressive than anticipated from clinical trials, and alternative treatments are beinu advocated increasingly for that reason, such as the anticonvulsants, carbamazepine and valproate.

Keywords

bipolar disorderlithiumcarbamazepineprophylaxis

Information

Type
Articles
Information
Acta Neuropsychiatrica , Volume 12 , Issue 3 , September 2000 , pp. 120 - 121
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Schou, M. Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 1998:31:210–215.CrossRefGoogle ScholarPubMed
2.Bauer, M, Ahrens, B. Bipolar disorder: A practical guide to drug treatment. CNS Drugs 1996:6:35–52.CrossRefGoogle Scholar
3.Silverstone, T, Romans, S. Long term treatment of bipolar disorder. Drugs 1996:51:367–382.CrossRefGoogle ScholarPubMed
4.Post, RM, Denicoff, KD, Frye, MA, Leverich, GS. Re-evaluating carbamazepine prophylaxis in bipolar disorder. Br J Psychiatry 1997:170:202–204.CrossRefGoogle Scholar
5.Okuma, T, Inanaga, K, Otsuki, S. et al.A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology 1981:73:95–96.CrossRefGoogle ScholarPubMed
6.Coxhead, N, Silvorstone, T, Cookson, J. Carbamazepine Versus Lithium in the Prophylaxis of Bipolar Affective Disorder. Acta Psychiatr Scand 1992:85:114–118.CrossRefGoogle ScholarPubMed
7.Greil, W, Ludwigmayorhofer, W, Erazo, N, Schochlin, C, Schmidt, S, Engel, RRet al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders – A randomised study. J Affect Disord 1997:43:151–161.CrossRefGoogle ScholarPubMed
8.Denicoff, KD, SmithJackson, EE, Disney, ER, Ali, SO, Loverich, GS, Post, RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997:58:470–478.CrossRefGoogle ScholarPubMed
9.Greil, W, Kleindienst, N, Erazo, N, MullerOerlinghausen, B. Differential responso to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998:18:455–460.CrossRefGoogle Scholar
10.Greil, W, Kleindienst, N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar 1 disorder. Int Clin Psychopharmacol 1999:14:277–281.CrossRefGoogle Scholar
11.Grof, P. Has the effectiveness of lithium changed? Impact of (he variety of lithium's effects. Neuropsychopharmacology 1998:19:183–188.CrossRefGoogle Scholar
12.Kleindienst, N, Greil, W, Ruger, B, Moller, HJ. The prophylactic efficacy of lithium – transient or persistent? Eur Arch Psychiatr Clin Neurosa 1999:249:144–149.CrossRefGoogle ScholarPubMed